Novavax (NVAX) Profit Jumps on Milestone

Novavax reported a surprise Q2 2025 GAAP profit of $0.62 EPS, reversing an expected loss, on revenue of $239 million, which significantly exceeded analyst estimates despite being down 42.4% year-over-year. This outperformance was largely due to a $175 million milestone payment from Sanofi following U.S. regulatory approval of Nuvaxovid, underscoring Novavax's strategic pivot towards a partnership-led revenue model and away from direct product sales. The company also substantially cut operational expenses, though future financial performance will increasingly depend on securing additional milestone payments and the commercial success of its partners.

Analysis

Novavax reported a significant top-and bottom-line beat for Q2 2025, posting a surprise GAAP EPS of $0.62 against an expected loss and revenue of $239 million that surpassed estimates by over 50%. However, these headline figures are primarily artifacts of a fundamental business model transition rather than underlying operational growth. The results were driven by a one-time $175 million milestone payment from Sanofi, triggered by the U.S. FDA approval of Nuvaxovid. This masks the sharp 42.4% year-over-year revenue decline and a 37.4% drop in EPS, reflecting the managed wind-down of its direct sales operations. Product sales have collapsed to just $11 million as the company pivots to a partnership-led model, relying on licensing and royalties, which constituted $229 million of revenue this quarter. This strategic shift is further evidenced by steep cuts in operating expenses, with SG&A falling 57% as commercialization responsibilities are transferred to partners. While the company's balance sheet has strengthened, with working capital swinging to a positive $530 million, future financial performance is now characterized by high uncertainty and volatility. Revenue will be 'lumpy,' dependent on achieving regulatory and commercial milestones, and the company has explicitly stated it will not advance key pipeline assets, like its COVID-Influenza vaccine, without securing external funding from partners.

Key Decisions for Investors

• Investors should re-evaluate Novavax as a high-risk R&D licensing entity whose value is now tied to event-driven milestone payments and future royalty streams, not predictable product sales.
• Monitor the successful transfer of marketing authorizations to Sanofi, expected in Q4 2025, which should unlock an additional $50 million milestone payment and provide the first test of the new partnership-centric model.
• While the raised FY2025 revenue guidance is positive, the lack of clarity on future royalty rates from Sanofi's commercialization efforts represents a primary risk and a critical variable for long-term valuation.
• The company's dependency on securing new partners for its pipeline, particularly for its late-stage COVID-Influenza-Combination vaccine, is a key catalyst to watch, as management has confirmed it will not self-fund further development.